Neoleukin Therapeutics (NASDAQ:NLTX) Trading Down 3.6% – Should You Sell?

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX)’s share price fell 3.6% on Tuesday . The company traded as low as $16.75 and last traded at $17.28. 160,539 shares changed hands during mid-day trading, an increase of 220% from the average session volume of 50,104 shares. The stock had previously closed at $17.92.

Neoleukin Therapeutics Stock Performance

The business’s 50 day moving average price is $21.54 and its 200-day moving average price is $22.09. The company has a market cap of $162.40 million, a price-to-earnings ratio of -5.56 and a beta of 1.11.

Neoleukin Therapeutics Company Profile

Neoleukin Therapeutics, Inc is a clinical‐stage biotechnology company focused on the design and development of de novo protein therapeutics for the treatment of cancer and immune‐mediated diseases. Leveraging computational protein engineering, the company creates novel cytokine mimetics intended to provide targeted immune activation while minimizing the toxicities associated with natural cytokines. This platform is anchored by proprietary algorithms and structure‐based design tools that enable the rapid generation of therapeutic candidates with optimized stability, affinity and specificity.

The company’s lead candidate, NL-201, is a next‐generation cytokine therapy designed to engage interleukin‐2 and interleukin‐15 receptors on immune effector cells, with the goal of enhancing anti‐tumor responses.